Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
2012 · New England Journal of Medicine · 7,903 citations
https://doi.org/10.1056/nejmoa1200694
O
Omid Hamid
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
858
Papers
83.4K
Citations
96
h-index
313
i10-index
Omid Hamid is an academic researcher from Northern Border University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 96, co-authored 730 publications.
ORCID: 0000-0002-8238-4655Papers by this author
worksPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 6,155 citations
https://doi.org/10.1056/nejmoa1501824
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · New England Journal of Medicine · 5,734 citations
https://doi.org/10.1056/nejmoa1503093
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
2014 · Nature · 5,183 citations
https://doi.org/10.1038/nature14011
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
2017 · The Lancet · 1,214 citations
https://doi.org/10.1016/s0140-6736(17)31601-x
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
2019 · Annals of Oncology · 920 citations
https://doi.org/10.1093/annonc/mdz011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat